Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 3/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.37 |
| ▸ | MMP3 | P08254 | 3/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | FCER2 | P06734 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | IL1RN | P18510 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021260 | 0.87 | HDAC8 (0.46) | ERAP2ERAP1LNPEPBIRC2MME | |
| SCHEMBL27427799 | 0.87 | HDAC8 (0.46) | ERAP2ERAP1LNPEPBIRC2MME | |
| SCHEMBL7081675 | 0.84 | GRIK1 (0.37) | ERAP2ERAP1LNPEPBIRC2GRIK1 | |
| SCHEMBL7134376 | 0.84 | GRIK1 (0.37) | ERAP2ERAP1LNPEPBIRC2GRIK1 | |
| SCHEMBL7085940 | 0.82 | GRIK1 (0.36) | BIRC2GRIK1GRIK2HDAC1HDAC2 | |
| SCHEMBL7085892 | 0.77 | GRIK1 (0.46) | GRIK1GRIK2HDAC1HDAC2HDAC8 | |
| SCHEMBL7082795 | 0.77 | GRIK1 (0.46) | GRIK1GRIK2HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL11172909 | 0.75 | DPP8 (0.45) | ERAP2ERAP1LNPEPMMP9CA12 | |
| SCHEMBL7082813 | 0.74 | GRIK1 (0.38) | BIRC2GRIK1GRIK2HDAC3HDAC4 | |
| SCHEMBL31057050 | 0.73 | HDAC8 (0.52) | GRIK1GRIK2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330429-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-07-30 | — | — | EP | claimed |
| US-6521790-B2 | A most preferred compound is (2R)-2-propyl-4-hexynamide, an analog of valproic acid. treating seizures, migraine, psychiatric disorders, neuropathic pain and restlessness syndrome; neuroprotecting a cerebral insult; | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | claimed |
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | ABBVIE INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002036546-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-10 | — | — | WO | claimed |
| EP-1330429-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6521790-B2 | A most preferred compound is (2R)-2-propyl-4-hexynamide, an analog of valproic acid. treating seizures, migraine, psychiatric disorders, neuropathic pain and restlessness syndrome; neuroprotecting a cerebral insult; | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | ABBVIE INC. | 2002-09-05 | — | — | US | disclosed |
| WO-2002036546-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | SCN1A, FAAH2, SCN1B | ERAP2 2144/4885ERAP1 2318/4885LNPEP 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.